Fig. 5: Neogenin/Merlin modulates EMT to inhibit tumor cell malignancy.
From: Neogenin suppresses tumor progression and metastasis via inhibiting Merlin/YAP signaling
A Representative image of IHC staining (up) and the correlation between Neogenin and Merlin (down) in primary tumors from CRC patients. Scale bars 50 μm. B NEO1 downregulates the expression of E-cad in CRC cells, but interfering with NF2 expression reverses the inhibition. HCT 116 cells transduced with lentivirus for NEO1 and siRNA for NF2 was applied for WB assay. siNC was used as control. C Representative IHC staining of Neogenin, Merlin, and vimentin in primary tumors from CRC patients. Scale bars 20 μm. D–F NEO1 suppresses the motility of CRC cells, but interfering with NF2 expression reverses the inhibitory effect. HCT 116 cells transduced with lentivirus for NEO1 and siRNA for NF2 was applied for migration assay (D, E) and invasion assay (F). siNC was used as control. The bar chart represents the quantification of migration assay (D, E) and invasion assay (F). Data represent means ± SD. *p < 0.05, **p < 0.001, ***p < 0.0001 compared with EV group by multiple t-tests or two-tailed Student’s t-test (D–F). #p < 0.05, ##p < 0.001, ###p < 0.0001 compared with NEO1/siNC group. See also Supplementary Fig. S6.
